This company listing is no longer active
EII0 Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥54.17 |
| 52 Week High | JP¥70.86 |
| 52 Week Low | JP¥36.61 |
| Beta | 0.17 |
| 11 Month Change | -5.31% |
| 3 Month Change | -20.01% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 34.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| EII0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.7% | 0.09% |
| 1Y | n/a | -18.7% | 3.1% |
Return vs Industry: Insufficient data to determine how EII0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how EII0 performed against the German Market.
Price Volatility
| EII0 volatility | |
|---|---|
| EII0 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: EII0's share price has been volatile over the past 3 months.
Volatility Over Time: EII0's weekly volatility has decreased from 10% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,322 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma.
Eisai Co., Ltd. Fundamentals Summary
| EII0 fundamental statistics | |
|---|---|
| Market cap | €14.46b |
| Earnings (TTM) | €183.92m |
| Revenue (TTM) | €5.08b |
78.6x
P/E Ratio2.8x
P/S RatioIs EII0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EII0 income statement (TTM) | |
|---|---|
| Revenue | JP¥737.10b |
| Cost of Revenue | JP¥190.01b |
| Gross Profit | JP¥547.09b |
| Other Expenses | JP¥520.38b |
| Earnings | JP¥26.71b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 93.12 |
| Gross Margin | 74.22% |
| Net Profit Margin | 3.62% |
| Debt/Equity Ratio | 18.8% |
How did EII0 perform over the long term?
See historical performance and comparison